Levy Adam D.
Transaction: 08/04/2026
SELL
Change
-1,142
Price
$1.57
Filing
08/06/2026
Type
SELL
Acrivon Therapeutics, Inc. Common Stock
ACRV • Biotechnology
$2.13
▲ +0.07 (+3.40%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$89.12M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.02Healthy liquidity · 7.69Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:28 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$2.13
Change3.40%
Shares Out41.84M
Market Cap$89.12M
Enterprise Value$1.28M
52W Range1.26 - 3.56
Beta1.86
P/E-1.20
P/B1.03
P/FCF-1.39
EV/EBITDA-0.02
EV/FCF-0.02
Price$2.13
Change3.40%
Shares Out41.84M
Market Cap$89.12M
Enterprise Value$1.28M
52W Range1.26 - 3.56
Beta1.86
P/E-1.20
P/B1.03
P/FCF-1.39
EV/EBITDA-0.02
EV/FCF-0.02
Earnings Yield-83.28%
FCF Yield-71.97%
Dividend Yield0.00%
Gross Margin0.00%
Oper. Margin0.00%
Profit Margin0.00%
Debt/Eq0.02
Current Ratio7.69
Quick Ratio7.69
Target$21.83
Target Upside924.88%
Target Median$20.00
Target Range17.00 - 30.00
Volume421.70K
Avg Volume455.56K
EPS Surprise0.00
Investment DNA
How strong this company looks for long-term investors
48
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
76/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
95/100
Why this score▼
Manageable debt level · 0.02Healthy liquidity · 7.69Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 10 analyst votes · 2026-09-05
95/100
Bullish
Bullish
9
Hold
1
Bearish
0
Price Target
2026-08-14
Low
$17.00
Mean
$21.83
Median
$20.00
High
$30.00
Insider Transactions
Recent executive and insider activity
Miller Mary
Transaction: 07/21/2026
SELL
Change
-573
Price
$1.76
Filing
07/23/2026
Type
SELL
BAUM CHARLES M
Transaction: 06/17/2026
BUY
Change
+20,275
Price
$1.52
Filing
06/22/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| Levy Adam D. | SELL | -1,142 | $1.57 | 08/04/2026 | 08/06/2026 |
| Miller Mary | SELL | -573 | $1.76 | 07/21/2026 | 07/23/2026 |
| BAUM CHARLES M | BUY | +20,275 | $1.52 | 06/17/2026 | 06/22/2026 |
| DiRocco Derek | BUY | +20,275 | $1.52 | 06/17/2026 | 06/22/2026 |
| Magovcevic-Liebisch Ivana | BUY | +20,275 | $1.52 | 06/17/2026 | 06/22/2026 |
| Palani Santhosh | BUY | +20,275 | $1.52 | 06/17/2026 | 06/22/2026 |
| Shacham Sharon | BUY | +20,275 | $1.52 | 06/17/2026 | 06/22/2026 |
| TOMSICEK MICHAEL JOHN | BUY | +20,275 | $1.52 | 06/17/2026 | 06/22/2026 |
| RA CAPITAL MANAGEMENT, L.P. | BUY | +20,275 | $1.52 | 06/17/2026 | 06/22/2026 |
| Blume-Jensen Peter | SELL | -13,729 | $1.79 | 05/21/2026 | 05/26/2026 |
| Blume-Jensen Peter | BUY | +72,706 | Not reported | 05/18/2026 | 05/20/2026 |
| Devroe Eric | BUY | +72,981 | Not reported | 05/18/2026 | 05/20/2026 |
| Gamelin Erick | BUY | +38,584 | Not reported | 05/18/2026 | 05/20/2026 |
| Levy Adam D. | BUY | +46,167 | Not reported | 05/18/2026 | 05/20/2026 |
| Miller Mary | BUY | +49,830 | Not reported | 05/18/2026 | 05/20/2026 |
| Mirza Mansoor Raza | BUY | +38,817 | Not reported | 05/18/2026 | 05/20/2026 |
| Peterson Katharine | BUY | +14,227 | Not reported | 05/18/2026 | 05/20/2026 |
| BAUM CHARLES M | BUY | +9,366 | Not reported | 05/18/2026 | 05/20/2026 |
| DiRocco Derek | BUY | +9,366 | Not reported | 05/18/2026 | 05/20/2026 |
| Magovcevic-Liebisch Ivana | BUY | +9,366 | Not reported | 05/18/2026 | 05/20/2026 |